Comparison of teniloxazine and piracetam in alzheimer-type or vascular dementia

Eugenio Aguglia, Tommaso Caraceni, Silvia Genitrini, Antonio Falsaperla, Nicola Martucci, Ubaldo Bonuccelli, Giuseppe Nappi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

In recent years, various pharmacologic approaches to improve the cognitive function of elderly patients with dementia have been proposed. These approaches are based on the observation that the drugs used act either directly or indirectly on neurotransmitters and their precursors. Recent studies have shown that teniloxazine, a new chemical entity, acts on specific neurotransmitters, inhibiting cerebral re-uptake of noradrenaline, blocking serotoninergic transmission, and restoring normal energy metabolism in the brain. This study compared the effects of teniloxazine and piracetam on the specific behavioral symptoms of Alzheimer-type or vascular dementia. The trial was conducted in six centers throughout Italy and included 117 patients (46 women and 71 men), aged 47 to 80 years, with Alzheimer-type degenerative dementia (62 patients) or vascular dementia (55 patients). Patients were randomized to receive either teniloxazine 80 mg twice daily (n = 57) or piracetam 800 mg twice daily (n = 60) for 3 months. Patients took tablets at 8 AM and 6 PM. The two drugs were similar in efficacy in terms of improvement in somatic and psychosensorial symptoms, and cognitive and behavioral performance, assessed with the Sandoz Clinical Assessment Geriatric Rating Scale (P <0.01, analysis of variance between times). Both drugs improved short-term memory. Scores on the Hamilton Rating Scale for Depression showed a larger reduction with teniloxazine (26.4%) than with piracetam (16.8%), indicative of a good improvement in the initial depressive symptoms. Few adverse events occurred (7 with teniloxazine and 5 with piracetam); 1 patient treated with piracetam did not show up for the last visit and was considered a dropout. Both drugs were considered therapeutically safe.

Original languageEnglish
Pages (from-to)250-257
Number of pages8
JournalCurrent Therapeutic Research
Volume56
Issue number3
DOIs
Publication statusPublished - 1995

Fingerprint

Piracetam
Vascular Dementia
Alzheimer Disease
Pharmaceutical Preparations
Neurotransmitter Agents
Depression
Geriatric Assessment
Behavioral Symptoms
sufoxazine
Short-Term Memory
Cognition
Energy Metabolism
Italy
Tablets
Dementia
Norepinephrine
Analysis of Variance
Brain

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Medicine(all)

Cite this

Aguglia, E., Caraceni, T., Genitrini, S., Falsaperla, A., Martucci, N., Bonuccelli, U., & Nappi, G. (1995). Comparison of teniloxazine and piracetam in alzheimer-type or vascular dementia. Current Therapeutic Research, 56(3), 250-257. https://doi.org/10.1016/0011-393X(95)85030-9

Comparison of teniloxazine and piracetam in alzheimer-type or vascular dementia. / Aguglia, Eugenio; Caraceni, Tommaso; Genitrini, Silvia; Falsaperla, Antonio; Martucci, Nicola; Bonuccelli, Ubaldo; Nappi, Giuseppe.

In: Current Therapeutic Research, Vol. 56, No. 3, 1995, p. 250-257.

Research output: Contribution to journalArticle

Aguglia, E, Caraceni, T, Genitrini, S, Falsaperla, A, Martucci, N, Bonuccelli, U & Nappi, G 1995, 'Comparison of teniloxazine and piracetam in alzheimer-type or vascular dementia', Current Therapeutic Research, vol. 56, no. 3, pp. 250-257. https://doi.org/10.1016/0011-393X(95)85030-9
Aguglia E, Caraceni T, Genitrini S, Falsaperla A, Martucci N, Bonuccelli U et al. Comparison of teniloxazine and piracetam in alzheimer-type or vascular dementia. Current Therapeutic Research. 1995;56(3):250-257. https://doi.org/10.1016/0011-393X(95)85030-9
Aguglia, Eugenio ; Caraceni, Tommaso ; Genitrini, Silvia ; Falsaperla, Antonio ; Martucci, Nicola ; Bonuccelli, Ubaldo ; Nappi, Giuseppe. / Comparison of teniloxazine and piracetam in alzheimer-type or vascular dementia. In: Current Therapeutic Research. 1995 ; Vol. 56, No. 3. pp. 250-257.
@article{42365a836e7e4edca6aac1b4c80dff3a,
title = "Comparison of teniloxazine and piracetam in alzheimer-type or vascular dementia",
abstract = "In recent years, various pharmacologic approaches to improve the cognitive function of elderly patients with dementia have been proposed. These approaches are based on the observation that the drugs used act either directly or indirectly on neurotransmitters and their precursors. Recent studies have shown that teniloxazine, a new chemical entity, acts on specific neurotransmitters, inhibiting cerebral re-uptake of noradrenaline, blocking serotoninergic transmission, and restoring normal energy metabolism in the brain. This study compared the effects of teniloxazine and piracetam on the specific behavioral symptoms of Alzheimer-type or vascular dementia. The trial was conducted in six centers throughout Italy and included 117 patients (46 women and 71 men), aged 47 to 80 years, with Alzheimer-type degenerative dementia (62 patients) or vascular dementia (55 patients). Patients were randomized to receive either teniloxazine 80 mg twice daily (n = 57) or piracetam 800 mg twice daily (n = 60) for 3 months. Patients took tablets at 8 AM and 6 PM. The two drugs were similar in efficacy in terms of improvement in somatic and psychosensorial symptoms, and cognitive and behavioral performance, assessed with the Sandoz Clinical Assessment Geriatric Rating Scale (P <0.01, analysis of variance between times). Both drugs improved short-term memory. Scores on the Hamilton Rating Scale for Depression showed a larger reduction with teniloxazine (26.4{\%}) than with piracetam (16.8{\%}), indicative of a good improvement in the initial depressive symptoms. Few adverse events occurred (7 with teniloxazine and 5 with piracetam); 1 patient treated with piracetam did not show up for the last visit and was considered a dropout. Both drugs were considered therapeutically safe.",
author = "Eugenio Aguglia and Tommaso Caraceni and Silvia Genitrini and Antonio Falsaperla and Nicola Martucci and Ubaldo Bonuccelli and Giuseppe Nappi",
year = "1995",
doi = "10.1016/0011-393X(95)85030-9",
language = "English",
volume = "56",
pages = "250--257",
journal = "Current Therapeutic Research - Clinical and Experimental",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "3",

}

TY - JOUR

T1 - Comparison of teniloxazine and piracetam in alzheimer-type or vascular dementia

AU - Aguglia, Eugenio

AU - Caraceni, Tommaso

AU - Genitrini, Silvia

AU - Falsaperla, Antonio

AU - Martucci, Nicola

AU - Bonuccelli, Ubaldo

AU - Nappi, Giuseppe

PY - 1995

Y1 - 1995

N2 - In recent years, various pharmacologic approaches to improve the cognitive function of elderly patients with dementia have been proposed. These approaches are based on the observation that the drugs used act either directly or indirectly on neurotransmitters and their precursors. Recent studies have shown that teniloxazine, a new chemical entity, acts on specific neurotransmitters, inhibiting cerebral re-uptake of noradrenaline, blocking serotoninergic transmission, and restoring normal energy metabolism in the brain. This study compared the effects of teniloxazine and piracetam on the specific behavioral symptoms of Alzheimer-type or vascular dementia. The trial was conducted in six centers throughout Italy and included 117 patients (46 women and 71 men), aged 47 to 80 years, with Alzheimer-type degenerative dementia (62 patients) or vascular dementia (55 patients). Patients were randomized to receive either teniloxazine 80 mg twice daily (n = 57) or piracetam 800 mg twice daily (n = 60) for 3 months. Patients took tablets at 8 AM and 6 PM. The two drugs were similar in efficacy in terms of improvement in somatic and psychosensorial symptoms, and cognitive and behavioral performance, assessed with the Sandoz Clinical Assessment Geriatric Rating Scale (P <0.01, analysis of variance between times). Both drugs improved short-term memory. Scores on the Hamilton Rating Scale for Depression showed a larger reduction with teniloxazine (26.4%) than with piracetam (16.8%), indicative of a good improvement in the initial depressive symptoms. Few adverse events occurred (7 with teniloxazine and 5 with piracetam); 1 patient treated with piracetam did not show up for the last visit and was considered a dropout. Both drugs were considered therapeutically safe.

AB - In recent years, various pharmacologic approaches to improve the cognitive function of elderly patients with dementia have been proposed. These approaches are based on the observation that the drugs used act either directly or indirectly on neurotransmitters and their precursors. Recent studies have shown that teniloxazine, a new chemical entity, acts on specific neurotransmitters, inhibiting cerebral re-uptake of noradrenaline, blocking serotoninergic transmission, and restoring normal energy metabolism in the brain. This study compared the effects of teniloxazine and piracetam on the specific behavioral symptoms of Alzheimer-type or vascular dementia. The trial was conducted in six centers throughout Italy and included 117 patients (46 women and 71 men), aged 47 to 80 years, with Alzheimer-type degenerative dementia (62 patients) or vascular dementia (55 patients). Patients were randomized to receive either teniloxazine 80 mg twice daily (n = 57) or piracetam 800 mg twice daily (n = 60) for 3 months. Patients took tablets at 8 AM and 6 PM. The two drugs were similar in efficacy in terms of improvement in somatic and psychosensorial symptoms, and cognitive and behavioral performance, assessed with the Sandoz Clinical Assessment Geriatric Rating Scale (P <0.01, analysis of variance between times). Both drugs improved short-term memory. Scores on the Hamilton Rating Scale for Depression showed a larger reduction with teniloxazine (26.4%) than with piracetam (16.8%), indicative of a good improvement in the initial depressive symptoms. Few adverse events occurred (7 with teniloxazine and 5 with piracetam); 1 patient treated with piracetam did not show up for the last visit and was considered a dropout. Both drugs were considered therapeutically safe.

UR - http://www.scopus.com/inward/record.url?scp=0028910046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028910046&partnerID=8YFLogxK

U2 - 10.1016/0011-393X(95)85030-9

DO - 10.1016/0011-393X(95)85030-9

M3 - Article

AN - SCOPUS:0028910046

VL - 56

SP - 250

EP - 257

JO - Current Therapeutic Research - Clinical and Experimental

JF - Current Therapeutic Research - Clinical and Experimental

SN - 0011-393X

IS - 3

ER -